Chinese Investors Wary Of In-Licensing-Only Biotechs After IPO Setback

 
• By Dexter Jie Yan

The torpedoed IPO application of a Shanghai-based biotech has already triggered a ripple of unease among venture capitalists in China, with some signaling suspension of investment in similar ventures.

red flag raised for Chinese investors
Chinese exchange’s refusal of one biotech’s IPO request raises red flag to some investors. • Source: Alamy

More from China

More from Focus On Asia